Cite Filings / XLO / 0001193125-26-001580
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
8-K

Current Report

Xilio Therapeutics, Inc. · Filed 2026-01-05 · Acc 0001193125-26-001580

Regulation FD disclosure

  • Item 7.01 Regulation FD disclosure

From the SEC's structured data for this filing

Documents 1

  • 8-K Current Report , xlo-20260102.htm

Around this filing

  • 2026-01-08 8-K Results of operations · Executive or director change
  • 2026-01-05 4 CHIEF MEDICAL OFFICER acquired 16,625 shares (option exercise)
  • 2026-01-05 4 SVP, FINANCE AND ACCOUNTING sold 1,826 shares at $0.64 ($1,174)
  • 2026-01-05 4 Chief Financial Officer sold 7,030 shares at $0.64 ($4,522)
  • 2026-01-05 4 PRESIDENT AND CEO acquired 44,250 shares (option exercise)
  • 2026-01-05 8-K Regulation FD disclosure
  • 2025-11-25 8-K Executive or director change · Shareholder vote results

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)
  • SEC Structured Data (opens in new tab)
Loading xlo-20260102.htm…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…